Keywords: enablex, elderly, cognition, impairment, novartis, darifenacin, one-daily
Enablex in elderly: no cognition impairment
Article | 07 March 2005
Novartis' Enablex (darifenacin), a one-daily treatment for over-active bladder, does not impair cognition in elderly patients, according to a study ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
